DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer

  • Wong, Zee (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date23/10/24 → 22/10/29